Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis

Lorraine1; Albon, Robert F Kushner2; Melanie Davies3; John E Deanfield4; W Timothy Garvey5; Ole Kleist Jeppesen6; Usman Khalid6; Mikhail Kosiborod7; Peter Norkjaer Laursen6; Domenica M Rubino8; Subodh Verma9

1 Western Sussex Hospitals NHS Foundation Trust, St Richards Hospital, Chichester, UK
2 Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL,
3 Diabetes Research Centre, Department of Health Sciences, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, Leicester, UK;
4 Institute of Cardiovascular Science, University College London, London, UK
5 Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
6 Novo Nordisk A/S, Soborg, Denmark
7 Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA; 8 Washington Center for Weight Management and Research, Arlington, VA, USA
9 Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Unity Health Toronto, Toronto, ON, Canada

Clinical taxonomy: 
Treatments for diabetes
Type 2 diabetes mellitus
Resource taxonomy: 

ABCD Webinar Series

ABCD Webinars